Umecrine Cognition named Bruce Scharschmidt, MD, senior development adviser and a member of its board of directors.
Here are four points:
1. Dr. Scharschmidt most recently served as senior vice president and chief medical and development officer at Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015.
2. Board-certified in internal medicine and gastroenterology, he has previously served as chief of gastroenterology at University of California, San Francisco, helping launch the UCSF liver transplant program.
3. He has also previously served as an associate editor of Gastroenterology and editor-in-chief of the Journal of Clinical Investigation.
4. Umecrine Cognition, a Swedish company, primarily focuses on developing a treatment for overt hepatic encephalopathy.